Also categorized in BoardNews:
Corporate Boards: Shifting From Aging Men To New Generation Of Women?
x hide permanently

Vertex CEO’s Pay Falls 38% to $17.4M in Second Straight Decline

The Boston Globe

Vertex Pharmaceuticals Inc. CEO Jeffrey M. Leiden saw his total compensation drop 38 percent to $17.4 million last year, largely on a steep cut in his stock-option awards from the Boston-based biotech. It was the second year in a row that Leiden’s pay declined from a 2014 payout of $36.6 million that made him the highest-paid head of a Massachusetts public company and sparked some shareholder criticism...

Mentions: stock options MDC Partners